Research and Educational Scope Notice: This article provides scientific context for receptor pharmacology, peptide characterization, analytical documentation, cell-signaling studies, structural biology, and preclinical research interpretation. It does not provide instructions for human use, veterinary use, dosing, administration, formulation, treatment, diagnosis, or personal use.
Cagrilintide is a synthetic, N-terminally acylated, long-acting amylin analogue. It is commonly described as a dual amylin receptor/calcitonin receptor agonist because it can engage amylin receptor complexes and the calcitonin receptor in experimental receptor systems.
Its principal research value lies in studies of calcitonin-family receptor pharmacology, peptide-receptor recognition, G protein-coupled receptor signaling, receptor-complex architecture, and metabolic signaling biology.[1]

Amylin is a 37-amino-acid peptide hormone. Its receptors are formed when the calcitonin receptor (CTR) associates with receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3), producing AMY1R, AMY2R, and AMY3R, respectively.
Cagrilintide is therefore relevant for experimental comparison of CTR-only and CTR-plus-RAMP receptor systems.[2]
1. Molecular Identity and Structural Design
PubChem lists cagrilintide with the molecular formula C194H312N54O59S2, a molecular weight of approximately 4,409 g/mol, an exact mass of approximately 4,408.2582 Da, and CAS number 1415456-99-3.[3]
The peptide backbone contains 37 amino-acid residues and is derived from the amylin scaffold. It retains the characteristic intramolecular disulfide bridge between Cys2 and Cys7 and a C-terminal amide.
The N-terminal Lys residue is modified with a C20 fatty diacid through a γ-glutamyl linker, a design feature associated with albumin binding and prolonged exposure in the original development program.[1]
Relative to native human amylin, cagrilintide contains the substitutions N14E, V17R, A25P, S28P, S29P, and Y37P. The N14E and V17R substitutions were introduced as helix-stabilizing changes and can support an intramolecular interaction within the peptide helix.
The proline substitutions in the central and C-terminal regions reduce the β-sheet-forming tendency associated with native amylin aggregation.[1][4]
In the original development program, cagrilintide showed apparent solubility above 200 μM across the tested pH range of 3.0 to 8.0 and had a calculated isoelectric point of approximately 8.6.
The same program reported substantially delayed fibrillation behavior relative to early lead compounds under its defined thioflavin-T screening conditions. These observations are formulation- and assay-dependent and should not be interpreted as universal solubility or stability guarantees under all laboratory conditions.[1]
PDB entry 7BG0 should be described precisely: it is an X-ray structure of a maltose-binding protein fusion containing the non-lipidated cagrilintide backbone analogue, rather than a structure of the complete free lipidated cagrilintide molecule.[5]
2. Amylin Receptor Architecture and Receptor Pharmacology
Amylin receptors are heteromeric receptor complexes consisting of CTR and a RAMP protein. RAMP1, RAMP2, and RAMP3 generate AMY1R, AMY2R, and AMY3R, respectively.
CTR can also be expressed without a RAMP, but CTR-only systems should not be treated as interchangeable with amylin receptor complexes because RAMP association alters receptor phenotype, ligand interaction, and signaling behavior.[2]
| Receptor Complex | Composition | Cagrilintide Information | Research Interpretation |
|---|---|---|---|
| AMY1R | CTR + RAMP1 | Active cagrilintide-bound structural complexes have been reported. | Useful for RAMP1-dependent receptor pharmacology, ligand-recognition, and receptor-complex studies. |
| AMY2R | CTR + RAMP2 | Active cagrilintide-bound structural complexes have been reported. | Useful for comparative studies of RAMP2-dependent signaling and receptor phenotype. |
| AMY3R | CTR + RAMP3 | Historical functional EC50: 49 pM in the cited human assay; 134 pM in the cited rat assay. | Useful for RAMP3-dependent ligand binding, cAMP-linked signaling, and conformational-dynamics studies. |
| CTR(a) | Calcitonin receptor without a RAMP | Historical functional EC50: 62 pM in the cited human assay; 82 pM in the cited rat assay. | Should be analyzed separately from AMYR complexes because CTR-only receptor pharmacology is distinct. |
In the cited discovery assay, cagrilintide showed human AMY3R and human CTR(a) functional EC50 values of 49 pM and 62 pM, respectively, corresponding to an AMY3R/CTR potency ratio of approximately 1.3.
This ratio is best treated as an assay-specific comparative observation, not as a universal intrinsic selectivity constant and not as a method for confirming receptor subtype identity.[1]
Cryo-electron microscopy studies have resolved cagrilintide in active Gs-coupled AMY1R, AMY2R, AMY3R, and CTR complexes. These structures support an amylin-like receptor-binding mode while also identifying receptor-complex-specific conformational differences.
The structural findings should be interpreted in the context of the experimental receptor system and should not be generalized automatically across all cell types, tissues, or species.[4]
3. Interpretation of Functional Assays
Cagrilintide-related receptor studies may use cAMP accumulation, CRE-reporter activity, ligand binding, G protein recruitment, receptor internalization, receptor trafficking, or pathway-bias measurements.
Potency and efficacy values depend on receptor construct, RAMP isoform, host-cell background, receptor-expression level, assay buffer, incubation duration, endpoint, curve-fitting approach, and reference ligand.
Every receptor pharmacology report should state the receptor subtype, RAMP composition, species origin, host-cell system, ligand concentration range, exposure duration, assay endpoint, normalization method, and reference comparator.
A potency value should not be interpreted as a direct measurement of binding affinity, receptor residence time, receptor selectivity, or in vivo activity.
Interpretation Principle: A difference between two laboratories may reflect receptor expression, RAMP incorporation, assay sensitivity, cell background, incubation duration, or data normalization.
A single EC50 ratio should not be used alone to establish receptor assembly or receptor subtype identity.
4. Appropriate Research Applications
4.1 Recombinant Receptor Pharmacology
Cagrilintide may be used in controlled recombinant-cell experiments that compare signaling through CTR, AMY1R, AMY2R, and AMY3R.
Suitable research questions include receptor-subtype profiling, RAMP-dependent pharmacology, ligand-binding behavior, cAMP-linked signaling, receptor trafficking, and structure-function relationships.
4.2 Structural Biology and Molecular Recognition
The available structural datasets provide a framework for studying peptide-receptor recognition, bypass-motif formation, peptide conformational behavior, extracellular-domain interactions, transmembrane signaling, and the structural contribution of RAMP proteins.
The N-terminal lipid modification is only partially resolved in available cryo-EM datasets, so structural interpretations of the full acyl chain should remain cautious.[4]
4.3 Preclinical Research Interpretation
The original development program reported dose-dependent effects on food intake and prolonged pharmacokinetic exposure in rats.
These findings are useful as historical preclinical pharmacology observations, but they are not experimental protocols and should not be translated directly between species, strains, disease models, routes, diets, or study endpoints.[1]
Any animal study should be conducted only under approved institutional protocols, appropriate welfare oversight, qualified supervision, and a prospectively defined experimental design.
5. Certificate of Analysis and Analytical Documentation
Before using a peptide lot for quantitative receptor experiments or comparative studies, researchers should review a batch-specific Certificate of Analysis and supporting analytical records.
At minimum, the available documentation should be evaluated for chromatographic purity, mass-spectrometry identity confirmation, lot number, storage conditions, and any reported peptide-content, water-content, counterion, residual-solvent, or impurity information.
Reverse-phase HPLC and mass spectrometry answer different analytical questions. HPLC can provide chromatographic purity information under a defined method, while mass spectrometry supports molecular-mass identity confirmation.
Neither result alone establishes absolute peptide content, full impurity characterization, lot-to-lot equivalence, solution stability, aggregation status, or suitability for any specific downstream application.
For quantitative exposure-response work, HPLC area purity should not be treated as equivalent to absolute peptide content.
Where concentration accuracy is important, peptide content or assay data should be considered alongside identity and chromatographic purity information.
Analytical procedures should be suitable for their intended use. General analytical-validation principles emphasize that method performance must be demonstrated for the relevant purpose rather than inferred from a single chromatogram or isolated analytical result.
These principles are cited here as scientific quality-control context and do not, by themselves, establish GMP, pharmacopoeial, ICH, or regulatory compliance for a specific research material.[6]
Residual-solvent information should be interpreted only when the solvent identity, analytical method, reporting unit, batch-specific result, and applicable internal specification are stated.
It is not scientifically appropriate to claim conformity with a residual-solvent standard when these details are absent.[7]
6. Storage, Solubility, and Handling Boundaries
Storage conditions should follow the supplier’s batch-specific label, Certificate of Analysis, and validated laboratory procedures.
No universal storage period, solution-stability period, or freeze-thaw tolerance should be assumed without lot-specific supporting data.
Because cagrilintide contains a lipidated N-terminus, it may display amphiphilic solution behavior. Published solubility findings were generated in defined screening conditions and should not be extrapolated automatically to all solvents, buffers, concentrations, surfaces, or storage intervals.
Laboratories should verify solvent compatibility, adsorption behavior, concentration accuracy, precipitation risk, and solution stability within their own validated experimental system.
For reproducibility, laboratory records should document the material lot number, storage history, preparation date, final analytical concentration, assay matrix, exposure duration, and any observed precipitation, adsorption, degradation, or chromatographic change.
7. Summary
Cagrilintide is a lipidated, long-acting amylin analogue with activity at amylin receptor complexes and CTR.
Its 37-residue peptide backbone contains the substitutions N14E, V17R, A25P, S28P, S29P, and Y37P relative to native human amylin, together with N-terminal C20 fatty-diacid lipidation through a γ-glutamyl linker.
The compound is useful for controlled research in calcitonin-family receptor pharmacology, RAMP-dependent receptor biology, cell signaling, molecular recognition, structural biology, analytical characterization, and carefully designed preclinical research.
Scientifically reliable interpretation requires explicit reporting of receptor composition, assay system, batch-specific analytical documentation, and experiment-specific handling conditions.
References
- Kruse T, Hansen JL, Dahl K, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry. 2021;64(15):11183-11194.
https://doi.org/10.1021/acs.jmedchem.1c00565 - Cao J, Belousoff MJ, Liang YL, et al. A Structural Basis for Amylin Receptor Phenotype. Science. 2022;375(6587):eabm9609.
https://doi.org/10.1126/science.abm9609 - National Center for Biotechnology Information. PubChem Compound Summary for Cagrilintide.
https://pubchem.ncbi.nlm.nih.gov/compound/Cagrilintide - Cao J, Belousoff MJ, Johnson RM, et al. Structural and Dynamic Features of Cagrilintide Binding to Calcitonin and Amylin Receptors. Nature Communications. 2025;16:3389.
https://www.nature.com/articles/s41467-025-58680-y - RCSB Protein Data Bank. 7BG0: Fusion of MBP and the Backbone of the Long-Acting Amylin Analog AM833.
https://www.rcsb.org/structure/7BG0 - International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures.
https://database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guideline_2023_1130_ErrorCorrection_2025.pdf - International Council for Harmonisation. ICH Q3C(R8): Impurities: Guideline for Residual Solvents.
https://database.ich.org/sites/default/files/ICH_Q3C-R8_Guideline_Step4_2021_0422_1.pdf
Scientific Disclaimer: This article is intended for educational and laboratory-research context only. It does not provide medical advice, clinical advice, diagnostic advice, treatment advice, veterinary advice, dosing guidance, administration guidance, formulation instructions, or instructions for personal use.
For a side-by-side look at structure, receptor selectivity and how to tell the two amylin analogs apart analytically, see our guide to eloralintide vs cagrilintide. For the AMY1R-preferring comparator material, see the Eloralintide peptide (LY3841136) product page.